- Novo, Lilly Stocks Rise. Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. Barron’s
- Mapping the effectiveness and risks of GLP-1 receptor agonists Nature.com
- Do GLP-1 drugs have health risks beyond their weight loss benefits? Medical News Today
- Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises New York Post
- Sweeping review suggests weight-loss drugs’ effect on 175 conditions The Washington Post